Alerts

Rosiglitazone: FDA Keeps It and the Europeans Yank It! The European Medicines Agency has recommended that rosiglitazone (Avandia) and all medications containing the drug be taken off the market. The FDA says rosiglitazone can stay, but requiring a risk evaluation and mitigation strategy (REMS) program with additional measures to ensure …

Merck expands Merck Helps, their free-of-charge vaccines and medicine program to individuals and families who earn up to 400% of the federal poverty level. To learn how your patients can benefit visit www.merckhelps.com.

Roche Suspends Dosing in Drug Trials for its GLP-1 Compound, Taspoglutide. See this week’s Item #6.

A1c Test for Diagnosis Not Perfect: Study (See this week’s Item #1.)

Switching Statins Often Leads to Wrong Doses. See this week’s Item #5.

Lilly Insulin Pens Being Discontinued Lilly will no longer be manufacturing the original Prefilled Pen that contains Humalog®, Humalog® Mix75/25™, and Humalog® Mix50/50™ as of January 1, 2011. In addition, there is currently a limited supply of the original Prefilled Pen devices containing the Humalog brand of insulin. The limited …

FDA issues hold on Avandia vs Actos study: Federal health officials say new patients should not be enrolled in the study, after experts last week said Avandia increases heart risks. FDA Okays New Hypertension Polypill Tribenzor by Daiichi Sankyo: The pill contains a combination of three hypertension drugs — olmesartan …

First-Void Urine Predicts Renal Events (See this week’s Item #1.)

Take Rosiglitazone Off the Market, Says FDA Staff, final decision this week. Pre-existing Conditions Covered by New High-Risk Insurance Pools Let your patients with diabetes and no insurance know that, beginning July 1st, individuals with pre-existing health conditions as diabetes are eligible to enroll in a temporary high-risk insurance pool, …

Look for our Special Edition on the ADA’s 70th Scientific Sessions Symposium this Tuesday!